scispace - formally typeset
P

Paul Morris

Researcher at University of Sheffield

Publications -  283
Citations -  12193

Paul Morris is an academic researcher from University of Sheffield. The author has contributed to research in topics: Fractional flow reserve & Medicine. The author has an hindex of 49, co-authored 252 publications receiving 10739 citations. Previous affiliations of Paul Morris include Johns Hopkins University & Center for Complex Systems and Brain Sciences.

Papers
More filters
Proceedings Article

Planning in interplanetary space: theory and practice

TL;DR: This paper describes the RAX Planner/Scheduler (RAX-PS), both in terms of the underlying planning framework and the fielded planner, as a system capable of building concurrent plans with over a hundred tasks within the performance requirements of operational, mission-critical software.
Journal ArticleDOI

Computational fluid dynamics modelling in cardiovascular medicine

TL;DR: The adoption of CFD modelling signals a new era in cardiovascular medicine and a number of academic and commercial groups are addressing the associated methodological, regulatory, education- and service-related challenges.
Proceedings Article

Dynamic control of plans with temporal uncertainty

TL;DR: This paper resolves the complexity issue for Dynamic Controllability and shows how to efficiently execute networks whose status has been verified.
Journal ArticleDOI

Virtual Fractional Flow Reserve From Coronary Angiography: Modeling the Significance of Coronary Lesions: Results From the VIRTU-1 (VIRTUal Fractional Flow Reserve From Coronary Angiography) Study

TL;DR: A computer model that accurately predicts myocardial fractional flow reserve (FFR) from angiographic images alone, in patients with coronary artery disease, was developed and was reliably predicted without the need for invasive measurements or inducing hyperemia.
Journal ArticleDOI

Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life.

TL;DR: Testosterone replacement therapy in hypogonadal men delays time to ischaemia, improves mood, and is associated with potentially beneficial reductions of total cholesterol and serum tumour necrosis factor α.